Searched for
SUN PHARMA Q3 REVENUE
Buy, Sell or Hold: Goldman Sachs maintains sell on Bharat Dynamics; HDFC Securities maintains buy on IndiaMART InterMESHBrokerages remain divided on two stocks. Goldman Sachs retained its 'Sell' rating on Bharat Dynamics, raising the target price marginally t...- Alera Group data breach settlement: Americans could get up to $3,500 in settlement payouts-know who’s eligible and the claim deadlineAmericans have a limited window to claim up to $3,500 from a $2 million settlement with Alera Group Inc. The insurance firm faced accusatio...
- Nominal GDP growth could fuel largecap recovery; pharma, auto ancillaries remain preferred bets: Shreyash DevalkarIndian stock markets are defying foreign investor caution, driven by resilient June-quarter earnings. Companies are navigating geopolitical...
- Honasa Consumer to acquire majority stake in Fluence Pharma at Rs 135-crore valuationHonasa Consumer has secured a majority stake in Mumbai's hair therapy brand Fluence Pharma for Rs 135 crore. This move marks the company's ...
- Honasa Consumer enters nutraceuticals segment; to acquires 58 pc stake in Fluence PharmaHonasa Consumer, parent of Mamaearth, is acquiring a 58% stake in nutraceuticals firm Fluence Pharma for Rs 135 crore, marking its entry in...
- Biosimilars and innovation will drive Indian pharma's next growth phase: Vishal ManchandaIndia's pharmaceutical sector is pivoting beyond generics, with companies aggressively pursuing growth in biosimilars, nutraceuticals, and ...
- Meesho shares rise 2% as Citi initiates coverage with Buy rating. Here's whyInternational brokerage Citi initiated coverage on Meesho with a 'Buy' rating, setting a target price of Rs 210 and anticipating a 23% upsi...
- Bharat Electronics shares in focus after defence PSU wins orders worth Rs 1,081 croreBharat Electronics shares are in focus following a significant Rs 1,081 crore order win, adding to previous gains. The defence PSU reported...
- Central Drugs Laboratories find 46 drug samples not of standard quality for MayHealth officials revealed that in May 2026, 46 drug samples tested by Central Drugs Laboratories and 113 by State Drugs Testing Laboratorie...
- Cochin Shipyard shares fall 3% amid buzz around OFS at 8% discountCochin Shipyard shares dipped Monday following reports of a potential government Offer for Sale (OFS) at a discount. The government, aiming...
- Reliance, financials and defence top investment picks as market leadership broadens: Rahul ShahReliance Industries is poised for a turnaround, with strong earnings, a Jio Platforms IPO, and AI/energy investments promising significant ...
- Cipla shares jump 4% as Citi puts stock on 90-day catalyst watch. What's driving the optimism?Cipla's stock surged following Citi's 'Buy' rating and a 90-day Positive Catalyst Watch. The brokerage anticipates growth from potential US...
- Stocks in news: Sun Pharma, Tech Mahindra, Tata Motors, Voltas, ONGCIndian markets saw a dip on Friday, with IT stocks leading the decline. Analysts suggest profit-taking occurred near the 24,150 mark. Despi...
- Sun Pharma adds Innovcare to its fold in Rs 271.2 crore all-cash transactionIndia's largest drugmaker, Sun Pharma, is set to acquire Mumbai-based Innovcare Lifesciences for approximately $28.7 million in an all-cash...
- Accenture signals caution, but analysts see long-term IT opportunityAccenture's earnings signal tough times for IT services. Indian IT firms face weak demand and cautious client spending. While valuations ar...
- TCS, Infosys, Wipro, other IT stocks crash up to 8% as Accenture lowers FY26 guidanceIndian IT stocks, including TCS and Infosys, tumbled up to 8% after Accenture lowered its annual revenue growth forecast, signaling continu...
- Reality Check: What triggered Accenture's historic stock plungeAccenture's biggest-ever stock plunge was driven by weaker revenue guidance, slowing bookings and rising investor concerns that AI-led disr...
- Accenture logs $18 billion Q3 revenue, revenue misses estimatesAccenture's Q3 FY26 results revealed a slowdown in IT demand, with the company missing revenue estimates and lowering its full-year guidanc...
- Accenture cuts revenue outlook, stock crashes 17%Accenture has lowered its annual revenue growth forecast. Companies are still cautious about spending on technology. This is happening even...
- Accenture net income rises to $2.39 billion during March-May quarterAccenture announced strong financial results for its March-May quarter. The IT services giant posted a net income of USD 2.39 billion, an i...
Load More
